We compared the erythropoiesis-stimulating effects of ultralow doses of erythropoietin receptors and antibodies to erythropoietin in intact mice. Antibodies to erythropoietin, but not erythropoietin receptors, possessed considerable erythropoiesis-activating properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1024786914967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost Minimized Immunoaffinity Purification of EPO and Its Analogs in Doping Control-A Step-by-Step Protocol for Human Urine and Blood.
Drug Test Anal
January 2025
European Monitoring Center for Emerging Doping Agents, German Sport University Cologne, Cologne, Germany.
A cost minimized immunoaffinity protocol was developed, which allows the direct purification of ERAs (urinary and recombinant human EPO, Darbepoetin, EPO-Fc, CERA) from human urine. The method applies magnetic beads and needs no covalent immobilization of the capture antibody. It requires only 10 mL of urine, 1 μg of anti-EPO antibody, and 25 μL of bead slurry.
View Article and Find Full Text PDFUnlabelled: Malaria, caused by spp., is a global health concern linked to anemia and increased mortality. Compensatory erythropoiesis seen during acute anemia results in an increased circulating reticulocyte count ( , immature RBC) a key factor in understanding the relationship between pre-existing anemia and burden.
View Article and Find Full Text PDFPharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity.
Pharm Res
January 2025
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ, 08854, USA.
Purpose: To investigate how obesity affects the pharmacokinetics of biologics in a rat model.
Method: Male Long-Evans rats were fed a high-fat diet from the age of 3 weeks and development of obesity was monitored by measuring body size and composition (fat and lean mass). The animals received nivolumab (1 and 8 mg/kg) or recombinant human erythropoietin (rHuEPO, 1000 IU/kg) by intravenous or subcutaneous injection.
Managing blood requirement in a rare P-null phenotype patient during the COVID pandemic in a resource-limited setting.
Asian J Transfus Sci
September 2022
Department of Paediatric Neurosurgery and Craniofacial Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi, Kerala, India.
We report the case of a 5-year-old girl with a rare P-null phenotype who presented for a neurosurgical procedure at our center. The case is unique as this patient was one of the two P-null phenotype cases reported in India and we report how we could successfully arrange a rare blood unit for her. As it was challenging to find a donor for her, autologous blood was collected.
View Article and Find Full Text PDFA Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation.
Am J Hematol
January 2025
Keros Therapeutics, Lexington, Massachusetts, USA.
Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as anemia impacts quality of life and potentially affects morbidity and mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!